Bildnachweis: bio:cap.
A new international platform in Berlin connects investors, start-ups and research to accelerate venture creation in biotechnology and artificial intelligence.
Artificial intelligence is transforming biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. bio:cap aims to strengthen this ecosystem by bringing together investors, start-ups, researchers and policymakers in a new international investival in Berlin.
Connecting science, start-ups and capital
From June 9–11, 2026, Berlin will host the premiere of bio:cap at the CityCube on the Berlin exhibition grounds. The event focuses on the intersection of life sciences, artificial intelligence and venture capital, connecting start-ups, research institutions, biotech and techbio companies with international investors and industry leaders. Europe is uniquely positioned to lead in life sciences. World-class universities, hospitals and research institutes generate groundbreaking discoveries, while start-ups translate scientific excellence into globally relevant innovations.
From discovery to investment
bio:cap spans the entire innovation cycle – from basic research and technology transfer to venture financing, commercialization and regulatory frameworks. Its goal is to accelerate the translation of scientific discoveries into scalable companies and real-world medical solutions. The programme highlights key trends shaping the sector, including AI in research and drug development, emerging therapeutic platforms such as gene and cell therapies, precision medicine and longevity, as well as venture financing strategies and exit pathways in biotechnology.
International leaders and global perspectives
Speakers include Nobel Prize laureate Prof. Dr. Stefan W. Hell of the Max Planck Institute for Multidisciplinary Sciences and Stefan Oelrich, Member of the Board of Management of Bayer AG and President of EFPIA. Members of the bio:cap Steering Committee, including Prof. Dr. Heyo K. Kroemer (Charité – Universitätsmedizin Berlin), Prof. Dr. Eicke Latz (Charité – Universitätsmedizin Berlin), Dr. Johannes Fruehauf (BioLabs and LabCentral), Prof. Dr. Ariel Stern (Hasso Plattner Institute) and Dr. Andreas Schmidt (Springboard Health Angels), will provide additional perspectives.
Networking across the life-science ecosystem
Curated matchmaking sessions and dedicated investor areas connect start-ups, academia, industry and venture capital. Side events across Berlin offer further opportunities for exchange and networking, including the bio:cap Investival Party on June 10 at the historic AVUS Tribüne. bio:cap is organised by Messe Berlin in cooperation with Charité – Universitätsmedizin Berlin, the Berlin Institute of Health in the Charité (BIH) and the Hasso Plattner Institute (HPI).
bio:cap 2026
June 9–11, 2026 | CityCube Berlin
More information: www.biocap-europe.com
